Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The World Hip Trauma Evaluation Four (WHiTE Four) study has now opened for recruitment in its first two sites (Northumbria Specialist Emergency Care Hospital in Northumberland, and John Radcliffe Hospital in Oxford). The study is a multi-centre, multi-surgeon, parallel, two arm, randomised controlled trial that will be running in 8+ hospitals in the UK. It is embedded within the WHiTE Comprehensive Cohort Study. The study includes a two-way superiority comparison between the X-Bolt Hip System (XHS) and Sliding Hip Screw fixations, and patients who present to A&E with a trochanteric fracture of the hip, who are 60 years of age and older, are eligible to participate. The trial will last a total of 38 months, with participant recruitment taking 18 months and final follow-up at 12 months post-surgery. Based upon 2013 data in the National Hip Fracture Database, the involved units perform approximately 800 of such procedures per year. The trial’s primary outcome is to quantify and draw inferences on observed differences in participants’ health status between the trial treatment groups at 4 months post-injury, and the secondary outcomes are to quantify and draw inferences on observed differences in the risk of all cause revision surgery, and  in the proportion of complications/radiographic changes within the first year post-injury between the trial treatment groups. 

For more information please visit https://www.ndorms.ox.ac.uk/clinical-trials/current-trials-and-studies/white 

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Three NIHR HTA grants awarded to Professor Tim Theologis

Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.

Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury

New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.